AbbVie, Inc. (ABBV): analysis and signal as of September 7, 2026
In short
The analysis assigns AbbVie a moderate signal, supported by a vote of three layers out of three and a score of 3,0. Operational quality and the upward revision of annual guidance justify this diagnosis, which the partially paid valuation premium and a complacency risk regime temper.
- Current signal
- moderate (vote 3/3)
- Deterministic score
- +3.0 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
AbbVie displays high operational quality, with a margin of 37,8 %, a free cash flow rate of 28 % and net debt to EBITDA of 0,6. Management has raised its annual guidance, with earnings per share expected to grow by 22 to 24 %. However, the price of 256-260 USD trades above its 200-session moving average, with a gap of 13,6 %, and the valuation premium appears partially paid. The macroeconomic expansion regime favours defensive healthcare. Conversely, the Cboe risk regime is in complacency, with a VIX9D/VIX3M slope of -32 % and a put/call ratio of 0,76 (z-score of -1,39), a sign of insufficient hedging. The stock retains a diversifying profile, with a correlation of 0,08 and a beta of -0,05, while the quarterly release of 23/10/2026 and the BCE rate increase of 10/09/2026 are the next milestones.
Bull case
The second quarter of 2026 proved solid, with revenues up 16 % and earnings per share of 2,03 USD. Annual guidance was raised, with earnings per share of between 8,25 and 8,40 USD, representing growth of 22 to 24 %. Free cash flow reached 2,9 billion dollars over the quarter and the 2 billion dollars repurchase programme is 53 % executed. SKYRIZI advances 29 % and RINVOQ 36 % in the fourth quarter of 2026. Net debt to EBITDA remains very low at 0,6 and the group holds a wide competitive moat, typical of biopharma, with a high return on invested capital.
Bear case
The stock trades expensively for a mature biopharma company, with a PER of 24,9 on a trailing twelve-month basis and 30,5 on 2026 estimates. Skyrizi and Rinvoq begin price negotiations with CMS under the IRA for 2027, with an estimated impact of around 2 % of 2027 revenue. A BCE rate increase on 10/09/2026 penalises rate-sensitive stocks. The Cboe risk regime in complacency reflects weak hedging and a pullback risk. Insider transactions over 60 days include 63,4 % of disposals. Finally, analyst estimates diverge, ranging between 258 and 276 USD.
Scenarios
The analysis does not formalise probabilistic bull, central or bear scenarios. It retains two calendar milestones: the BCE rate increase of 10/09/2026 and the release of the third-quarter report on 23/10/2026.
Risks
The main risk comes from the market regime in complacency: the VIX9D/VIX3M slope of -32 % and the put/call ratio of 0,76 (z-score of -1,39) signal insufficient hedging and expose the stock to a pullback in the event of a reversal. The valuation premium, with a PER of 30,5 expected for 2026, leaves little room for operational disappointment. Pricing negotiations around Skyrizi and Rinvoq weigh about 2 % of 2027 revenue. Executive disposals, at 63,4 % of transactions over 60 days, contribute an unfavourable signal. The stock's diversifying profile, with a correlation of 0,08 and a beta of -0,05, does not remove these risks.
Market positioning (short sellers)
- Short interest / shares outstanding
- 1.04 %
- Days to cover
- 3.57
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| T3 2026 results and neuroscience pipeline |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| moderate (3/3) | The signal moves from weak to moderate. Dated new facts: AbbVie's official calendar, published on 07/09/2026, confirms the third-quarter report for 23/10/2026. The price of 260,21 USD as of 06/09/2026 sits above the 200-session moving average, with a gap of 13,6 %, and has crossed above the 50-session moving average (+0,9 %). Short interest declined 18,8 % compared with the previous settlement and stands at 1,04 % of the float as of 14/08/2026. The macroeconomic expansion regime, with a weighting of 0,58, favours defensive healthcare. | |
| weak (single draw, outside the three-draw protocol) | unchanged | |
| moderate (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What signal does the analysis assign to the AbbVie stock?
The analysis assigns a moderate signal, supported by a vote of three layers out of three and a score of 3,0. Operational quality, the upward revision of annual guidance and the macroeconomic expansion regime support the thesis. As a counterpoint, the partially paid valuation premium and a complacency risk regime prevent a higher signal.
What results did AbbVie report for the second quarter of 2026?
Revenues grew 16 % and earnings per share stand at 2,03 USD. Free cash flow reached 2,9 billion dollars over the quarter. Management raised its annual guidance, with earnings per share expected between 8,25 and 8,40 USD, representing growth of 22 to 24 %. The 2 billion dollars repurchase programme is 53 % executed.
What are the main bearish factors identified?
The valuation is high for a mature biopharma company, with a PER of 24,9 on a trailing twelve-month basis and 30,5 on 2026 estimates. Skyrizi and Rinvoq begin negotiations with CMS under the IRA, with an estimated impact of around 2 % of 2027 revenue. Executive disposals account for 63,4 % of transactions over 60 days and analyst estimates diverge between 258 and 276 USD.
Why was the signal raised from weak to moderate?
AbbVie's official calendar, published on 07/09/2026, confirms the release of the third-quarter report on 23/10/2026. The price of 260,21 USD as of 06/09/2026 trades above the 200-session moving average, with a gap of 13,6 %, and has crossed above the 50-session moving average (+0,9 %). Short interest declined 18,8 % and stands at 1,04 % of the float as of 14/08/2026.
What is the stock's correlation profile?
The stock shows a correlation of 0,08 with the market and a beta of -0,05, which makes it an asset with low sensitivity to general market moves. This diversifying profile is an asset in an expansion environment that favours defensive healthcare. This character does not, however, protect against a pullback linked to the complacency risk regime described by the Cboe analysis.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 8.01 Other Events; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 8.01 Other Events; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
- — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 7, 2026; this page was completed on September 11, 2026 at 12:14 (UTC).
- Interests: no position in the stock analysed (ABBV) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: Abbott Laboratories (ABT)
- All analysed stocks
- Public methodology